Can you name the initial fda approved cancer for keytruda?

What cancer was Keytruda initially approved for?

Keytruda, also known as pembrolizumab, was initially approved by the FDA on September 4, 2014, for the treatment of patients with metastatic melanoma, a type of skin cancer [1]. It was approved for use in patients whose disease had progressed after treatment with ipilimumab (Yervoy).

How is Keytruda's approval significant?

This approval marked a significant milestone in the treatment of melanoma, which is one of the most aggressive forms of skin cancer. Historically, ipilimumab had been the standard of care for treating metastatic melanoma, but it had its limitations. Keytruda's approval offered patients a new treatment option with a different mechanism of action, targeting the PD-1 protein on immune cells to help unleash an immune response against cancer cells.

What has been the impact of Keytruda's approval?

Since its initial approval, Keytruda has become a crucial treatment option for various types of cancer, including non-small cell lung cancer, head and neck cancer, kidney cancer, and more. Its approval has paved the way for the development of other immunotherapies, revolutionizing the treatment of cancer and improving patient outcomes [2]. Today, Keytruda is one of the most prescribed cancer treatments in the world, with numerous ongoing clinical trials exploring its potential applications in other types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/patent/US-8741493
[2] National Cancer Institute

DrugPatentWatch.com: A comprehensive database providing information on pharmaceutical patents, including Keytruda's patent status.